Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
Colorcon
Boehringer Ingelheim
Merck

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Rituximab; hyaluronidase (human recombinant) - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for rituximab; hyaluronidase (human recombinant)

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Emory UniversityPhase 2
Genentech, Inc.Phase 2
Fred Hutchinson Cancer Research CenterPhase 1

See all rituximab; hyaluronidase (human recombinant) clinical trials

Recent Litigation for rituximab; hyaluronidase (human recombinant)

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all rituximab; hyaluronidase (human recombinant) litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all rituximab; hyaluronidase (human recombinant) litigation

Patent Text Search: US Patents for rituximab; hyaluronidase (human recombinant)

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab; hyaluronidase (human recombinant)

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000027 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021
C00050 Luxembourg   Start Trial PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
2 50002-2015 Slovakia   Start Trial PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKesson
AstraZeneca
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.